Development Pipeline
Pipeline
Status
EF-001 (Cerebraca® Wafer)
EF-009 Wafer
HK-001
EF-031
TSCA-001
EF-011
EF-001 (Cerebraca® Wafer)
Brain Tumor Treatment | Implant
- IND application approved by USFDA and TFDA
- Orphan drug Designation (USFDA)
- A phase 1/2a clinical trial in Taiwan (CSR will be finalized by end of May in 2024)
- click for more information
EF-009 Wafer
Pancreatic Cancer Treatment | Implant
- IND application approved by USFDA and TFDA
- click for more information
HK-001
ALS Treatment | Oral Dosage Form
- IND application approved by USFDA and TFDA
- A phase 1 clinical trial in Taiwan is ongoing
- click for more information
EF-031
Solid Tumors Treatment | Oral Dosage Form
- Pre-clinical studies
- Prepared for IND application
- click for more information
TSCA-001
Spinocerebellar Ataxia Treatment | Oral Dosage Form
- Pre-clinical studies
- click for more information
EF-011
Idiopathic Pulmonary Fibrosis Treatment | Oral Dosage Form
- Pre-clinical studies
- click for more information
Partnering and Collaboration
Strategic Partnerships
- - -
Open to Collaborative Drug Development and Manufacturing
Out-licensing
- - -
Seeking Technology Licensing and Pharmaceutical Partnerships
In-licensing
- - -
Actively Exploring Collaborations for Promising Drugs and Combination Therapies
EFB is looking for the opportunity to cooperate with international pharmaceutical companies or venture capitals.
Please mail us on efbiotech@efbiotech.com
Partner
